Key Points
- To evaluate the antagonistic mechanisms and potency of prostanoid analogues EP 045, EP 092, and PTA2 against thromboxane- and prostaglandin-induced human platelet aggregation.
- Tested platelet aggregation in vitro using human platelet-rich plasma and plasma-free platelet suspensions challenged with TXA2, PGH2, stable thromboxane mimetics, ADP, PAF, and adrenaline.
- Performed Schild analysis to assess the competitive nature and affinity constant of antagonist binding, alongside assays for 5-HT release and cyclic AMP accumulation.
- EP 045 (20 μM) and EP 092 (1 μM) completely inhibited irreversible platelet aggregation induced by TXA2, PGH2, and stable mimetics, with Schild analysis confirming competitive antagonism for EP 045 (affinity constant: 1.1 × 10^7 M^-1).
- Both EP 045 and EP 092 selectively blocked the secondary aggregation phase induced by ADP, PAF, and adrenaline without altering cyclic AMP levels.
- PTA2 acted as a partial thromboxane agonist by inducing shape change, while also causing a weak cyclic AMP increase that contributed functional antagonism.
Structured PICO
PPopulationHuman platelets in vitro (diluted platelet-rich plasma and plasma-free platelet suspensions)
IInterventionProstanoid analogues EP 045, EP 092, and pinane thromboxane A2 (PTA2)
OOutcomePlatelet aggregation and 5-hydroxytryptamine (5-HT) releasesurrogate
EP 045 and EP 092 act as potent antagonists at the human platelet thromboxane receptor, inhibiting platelet aggregation without affecting primary aggregation waves induced by other agonists.